Thursday, September 22, 2016 9:33:19 PM
"By contrast, the objective of our Phase 3 1150-patient MINDSET study is to confirm the results of a 684-patient Phase 2 study that demonstrated statistically significant improvements on cognition and function," he said. "Based on today's news, and subject to FDA approval, intepirdine could now be the first drug of its class to be approved for the treatment of mild-to-moderate Alzheimer's disease – potentially becoming the first approved treatment for this disease since 2003."
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM